VAC 52416
Alternative Names: E. coli vaccine - Janssen; Escherichia coli bioconjugate vaccine - Janssen; ExPEC10V; JNJ-69968054; VAC-52416Latest Information Update: 28 Apr 2023
At a glance
- Originator Janssen Research & Development
- Class Conjugate vaccines; Escherichia coli vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Escherichia coli infections
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for phase-I development in Escherichia-coli-infections(Prevention) in Japan (IM, Injection)
- 19 Oct 2022 Adverse event and immunogenicity data from a phase I/IIa trial in Escherichia coli infections presented at the IDWeek 2022
- 29 Jul 2021 Phase-III clinical trials in Escherichia coli infections (Prevention) in USA, European Union (IM) (Johnson and Johnson pipeline, July 2021 )